Coalition Expects Higher Personalized Medicine Profile During User Fee Talks

Better coordination of device and drug review processes is crucial to the future of personalized medicine and are likely to be an important focus of upcoming user fee negotiations, says the Personalized Medicine Coalition's Amy Miller.

Better aligning diagnostic and drug review processes should be one key focus of upcoming user fee negotiations, says Amy Miller.

Miller is the executive VP of the Personalized Medicine Coalition (PMC), which includes members from the diagnostics and drug industries, as well as the medical, research and financial communities

More from Regulation

More from Policy & Regulation